Table 3.
Univariate and multivariate analysis of the whole cohort.
| Clinicopathologic features | Univariate analysis | multivariate analysis | ||
|---|---|---|---|---|
| X2 | P | HR(95%CI) | P | |
| OS | ||||
|
Genger
(male/female) |
0.096 | 0.757 | ||
|
Age
(≤65years old/65years old) |
0.039 | 0.843 | ||
|
ECOG
(2/0-1) |
0.007 | 0.935 | ||
|
First line treatment modality
(surgery/non-surgery) |
2.309 | 0.203 | ||
|
Recurrence type
(Local regional/others) |
0.244 | 0.622 | ||
|
Interval after treatment failure
(≤12 month/>12month) |
2.614 | 0.106 | ||
|
Camrelizumab combined modality
(Chemoradiotherapy/Others) |
3.821 | 0.047 | ||
|
Treatment related toxicity
(yes/no) |
7.529 | 0.006 | 0.440(0.198-.0980) | 0.044 |
|
Number of cycles of Camrelizumab used
(<6 cycles/≥6 cybles) |
13.144 | 0.000 | 0.341(0.137-0.847) | 0.021 |
| Short-term effects (PR/SD/PD) |
8.112 | 0.004 | 3.174(1.186-8.497) | 0.021 |
|
SIS score
(≤1/>1) |
14.354 | 0.000 | 2.749(1.091-6.930) | 0.030 |
|
CONUT score
(≤3/>3) |
11.633 | 0.001 | ||
| PFS | ||||
|
Genger
(male/female) |
0.095 | 0.757 | ||
|
Age
(≤65years old/65years old) |
0.001 | 0.973 | ||
|
ECOG
(2/0-1) |
0.474 | 0.492 | ||
|
First line treatment modality
(surgery/non-surgery) |
2.104 | 0.716 | ||
|
Recurrence type
(Local regional/others) |
0.068 | 0.565 | ||
|
Interval after treatment failure
(≤12 month/>12month) |
0.001 | 0.980 | ||
| Camrelizumab combined modality (Chemoradiotherapy/Others) | 4.426 | 0.035 | ||
|
Treatment related toxicity
(yes/no) |
0.000 | 0.995 | ||
|
Number of cycles of Camrelizumab used
(<6cycles/≥6cybles) |
6.100 | 0.014 | ||
|
Short-term effects
(PR/SD/PD) |
3.703 | 0.054 | ||
|
SIS score
(≤1/>1) |
14.812 | 0.000 | 3.784(1.479-9.677) | 0.005 |
|
CONUT score
(≤3/>3) |
10.018 | 0.002 | 2.355(1.012-5.481) | 0.047 |